Published : 16 Oct 2013

---

--cMet antagonist, PRS-110, to be the flagship program--

October 16, 2013 Freising, Germany; Naperville, USA: Pieris AG, a next generation therapeutic protein R&D company and Zydus Cadila, an innovative global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products have entered into an alliance for development and commercialization of multiple novel Anticalin®-based protein therapeutics, both companies announced today.

The collaboration combines Pieris' drug discovery and early development capabilities with Zydus' expertise in biologics development, regulatory affairs and biologics manufacturing. Under the terms of the agreement, Zydus will take the lead in advancing Anticalin drug candidates through formal pre-clinical development and into clinical development, undertaking drug development in accordance with ICH guidelines.

Zydus has been granted exclusive marketing rights in India and several other emerging markets, while Pieris retains exclusive marketing rights in key developed markets.

Aagami, Inc. a Naperville IL based Strategic and Global Advisory firm supported Pieris in this deal. Pieris CEO, Stephen Yoder, said, "With state-of-the-art manufacturing facilities and seasoned drug development team at Zydus, this collaboration will allow Pieris to unlock value on a global scale in a cost-effective manner, significantly expanding the number of proprietary Anticalin programs we can advance into clinical trials and beyond."

Dinesh Jain, Founder CEO of Aagami said "This deal realizes the great possibilities of innovative Pharmaceutical work from India and demonstrates how global companies can benefit by partnering with large Indian MNCs – a view we have been propagating".

For further information on the deal, please click on http://www.pieris-ag.com/news-events/news-events-recent-news-2013-1016.php 

 

 

About Pieris & Anticalins:

Pieris AG is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that are safer and more effective than conventional approaches. Exclusive to Pieris, Anticalins promise to address high-unmet medical needs and expand the potential of targeted therapeutics.

The company currently has a diverse proprietary pipeline and has, in addition to Zydus, ongoing R&D collaborations with Daiichi Sankyo, the Sanofi Group and Allergan. Privately held, Pieris has been funded by premier biotechnology-focused venture capital, including lead investors OrbiMed Advisors and Global Life Science Ventures.

For more information, please visit: www.pieris-ag.com.

Anticalins® are recombinantly engineered versions of human lipocalins, low-molecular weight polypeptides that naturally bind, store and transport a wide spectrum of molecules. To make Anticalins, Pieris makes discrete changes to those lipocalin amino acid positions responsible in endogenous ligand binding, thereby redirecting specificity away from the natural ligand and to virtually any target of interest. By utilizing an endogenous binding protein as a template, Pieris "hijacks" the natural function of the lipocalin to enable diverse therapeutic applications.

*Anticalin®, Anticalins® are registered trademarks of Pieris AG.

About Aagami:

Aagami Inc. a Strategic Consulting Firm focused on bringing success to Global Pharma, Biotech and Medical Devices companies in their initiatives for India, Asia and other emerging markets. Aagami Partners bring several decades of operational experience globally, connections at C-Level people with Indian Life-sciences companies and most importantly deep knowledge of India/Asia-business-practices. While Aagami serves clients from all over the world the major successful clients are from the US, Australia, EU, Japan, and Brazil.

For more information, please visit: www.aagami.com.